Natco Pharma - Covid-19 Drags FY21; New Launches To Drive FY22: ICICI Direct

An employee inspects a tray of Concor cardiovascular treatment tablets inside pharmaceutical laboratories. (Photographer: Martin Leissl/Bloomberg).

Natco Pharma - Covid-19 Drags FY21; New Launches To Drive FY22: ICICI Direct


BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Natco Pharma Ltd.’s Q4 FY21 revenues de-grew 27.2% YoY to Rs 331.3 crore due to decline across verticals.

Export formulations declined 27.6% YoY to Rs 158.8 crore due to significant drop in gTamiflu sales.

Domestic formulations de-grew 20.3% to Rs 81.8 crore amid a sharp fall in oncology sales.

Active pharmaceutical ingredient business declined 26.6% YoY Rs 70.8 crore.

Ebitda margins contracted 521 basis points YoY to 23%, mainly due to higher employee cost.

Ebitda fell 40.6% YoY to Rs 76.2 crore. Ensuing profit after tax declined 43.7% YoY to Rs 53 crore.

Click on the attachment to read the full report:

ICICI Direct Natco Q4FY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.